NP_001032827.1
[Other Products]
NCBI GenBank Nucleotide #
|
[Other Products]
UniProt Primary Accession #
|
[Other Products]
UniProt Secondary Accession #
UniProt Related Accession #
NCBI Official Full Name
nucleophosmin isoform 3
NCBI Official Synonym Full Names
nucleophosmin 1
NCBI Official Synonym Symbols
NCBI Protein Information
nucleophosmin
UniProt Protein Name
Nucleophosmin
UniProt Synonym Protein Names
Nucleolar phosphoprotein B23; Nucleolar protein NO38; Numatrin
UniProt Synonym Gene Names
NCBI Summary for NPM
The protein encoded by this gene is involved in several cellular processes, including centrosome duplication, protein chaperoning, and cell proliferation. The encoded phosphoprotein shuttles between the nucleolus, nucleus, and cytoplasm, chaperoning ribosomal proteins and core histones from the nucleus to the cytoplasm. This protein is also known to sequester the tumor suppressor ARF in the nucleolus, protecting it from degradation until it is needed. Mutations in this gene are associated with acute myeloid leukemia. Dozens of pseudogenes of this gene have been identified. [provided by RefSeq, Aug 2017]
UniProt Comments for NPM
Involved in diverse cellular processes such as ribosome biogenesis, centrosome duplication, protein chaperoning, histone assembly, cell proliferation, and regulation of tumor suppressors p53/TP53 and ARF. Binds ribosome presumably to drive ribosome nuclear export. Associated with nucleolar ribonucleoprotein structures and bind single-stranded nucleic acids. Acts as a chaperonin for the core histones H3, H2B and H4. Stimulates APEX1 endonuclease activity on apurinic/apyrimidinic (AP) double-stranded DNA but inhibits APEX1 endonuclease activity on AP single-stranded RNA. May exert a control of APEX1 endonuclease activity within nucleoli devoted to repair AP on rDNA and the removal of oxidized rRNA molecules. In concert with BRCA2, regulates centrosome duplication. Regulates centriole duplication: phosphorylation by PLK2 is able to trigger centriole replication. Negatively regulates the activation of EIF2AK2/PKR and suppresses apoptosis through inhibition of EIF2AK2/PKR autophosphorylation. Antagonizes the inhibitory effect of ATF5 on cell proliferation and relieves ATF5-induced G2/M blockade (PubMed:22528486). In complex with MYC enhances the transcription of MYC target genes (PubMed:25956029).
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice. It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
Products associated with anti-NPM antibody
Pathways associated with anti-NPM antibody
Diseases associated with anti-NPM antibody
Disease Name |
Pubmed Publications |
Leukemia, Myeloid, Acute Antibodies |
>478 publications with NPM and Leukemia, Myeloid, Acute |
Neoplasms Antibodies |
>448 publications with NPM and Neoplasms |
Cell Transformation, Neoplastic Antibodies |
>29 publications with NPM and Cell Transformation, Neoplastic |
Leukemia, Promyelocytic, Acute Antibodies |
>20 publications with NPM and Leukemia, Promyelocytic, Acute |
Carcinoma Antibodies |
>17 publications with NPM and Carcinoma |
Adenocarcinoma Antibodies |
>8 publications with NPM and Adenocarcinoma |
Breast Neoplasms Antibodies |
>8 publications with NPM and Breast Neoplasms |
Neoplasms, Experimental Antibodies |
>5 publications with NPM and Neoplasms, Experimental |
Neoplasm Metastasis Antibodies |
>4 publications with NPM and Neoplasm Metastasis |
Lung Neoplasms Antibodies |
>4 publications with NPM and Lung Neoplasms |
Organs/Tissues associated with anti-NPM antibody
|